These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14729635)

  • 21. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
    Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2 inhibitors: cancer trials test new uses for pain drug.
    Michalowski J
    J Natl Cancer Inst; 2002 Feb; 94(4):248-9. PubMed ID: 11854385
    [No Abstract]   [Full Text] [Related]  

  • 23. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective COX-2 inhibitors as chemopreventive and therapeutic agents.
    Grossman HB
    Drugs Today (Barc); 2003 Mar; 39(3):203-12. PubMed ID: 12730704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approach to angiogenesis inhibition based on cyclooxygenase-2.
    Masferrer J
    Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of inhibition of novel COX-2 inhibitors.
    Gierse J; Kurumbail R; Walker M; Hood B; Monahan J; Pawlitz J; Stegeman R; Stevens A; Kiefer J; Koboldt C; Moreland K; Rowlinson S; Marnett L; Pierce J; Carter J; Talley J; Isakson P; Seibert K
    Adv Exp Med Biol; 2002; 507():365-9. PubMed ID: 12664611
    [No Abstract]   [Full Text] [Related]  

  • 27. Analgesia and COX-2 inhibition.
    Dionne RA; Khan AA; Gordon SM
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S63-70. PubMed ID: 11695255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.
    Wu GS; Zou SQ; Liu ZR; Tang ZH; Wang JH
    World J Gastroenterol; 2003 Jun; 9(6):1302-6. PubMed ID: 12800245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
    Altorki NK; Port JL; Zhang F; Golijanin D; Thaler HT; Duffield-Lillico AJ; Subbaramaiah K; Dannenberg AJ
    Clin Cancer Res; 2005 Jun; 11(11):4191-7. PubMed ID: 15930356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
    Wang L; Chen W; Xie X; He Y; Bai X
    Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
    Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
    Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
    Pentland AP; Schoggins JW; Scott GA; Khan KN; Han R
    Carcinogenesis; 1999 Oct; 20(10):1939-44. PubMed ID: 10506108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
    Khan AA; Brahim JS; Rowan JS; Dionne RA
    Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
    Goldenberg MM
    Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.
    Tegeder I; Niederberger E; Vetter G; Bräutigam L; Geisslinger G
    J Neurochem; 2001 Nov; 79(4):777-86. PubMed ID: 11723170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
    Choy H; Milas L
    J Natl Cancer Inst; 2003 Oct; 95(19):1440-52. PubMed ID: 14519750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.